Despite these issues, the overall quality of evidence was considered high, reinforcing confidence in the validity and applicability of the findings for long-term obesity management using GLP-1 receptor agonists. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.